Thus, the involvement of CD93 in glioma-based immunological responses together with these immunosuppressive processes indicates that CD93-targeting precise therapies are within the bounds of probability, and this provides an available premise in regard to coordinating locally aberrant immunity activities, obstructing immunosuppressive invasion, and raising glioma sensitivity towards treatments (Burster et al. 2021). The gene discussed is CD93; the disease is central nervous system cancer.